Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03795311 |
Title评估 FOLFIRINOX3 贝伐单抗治疗结直肠癌患者的疗效和安全性（FOLFIRINOX 3） | 阶段
Phase 1, Phase 2
|
Date Added 2019-01-07 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FOLFIRINOX 贝伐单抗 |
标签
MSS/ MMRp
|
| NCT ID NCT03785249 |
TitleMRTX849 治疗 KRAS G12C 基因突变癌症患者的 1/2 期研究 KRYSTAL-1 | 阶段
第 1 阶段
|
Date Added 2018-12-24 |
地点
Alabama, United States
Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
afatinib, cetuximab, MRTX849, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03783403 |
TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | 阶段
第 1 阶段
|
Date Added 2018-12-21 |
地点
Alabama, United States
Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States 澳大利亚 加拿大 法国 意大利 大韩民国 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
CC-95251, cetuximab, Rituximab |
标签
MSS/ MMRp
|
| NCT ID NCT03772561 |
TitleAZD5363 + Olaparib + Durvalumab 治疗晚期或转移性实体瘤恶性肿瘤患者的 I 期研究 | 阶段
第 1 阶段
|
Date Added 2018-12-11 |
地点
新加坡
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
AZD5363+Olaparib+Durvalumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03745326 |
Title给 HLA-A*11:01 患者注射用识别变异 RAS G12D 变异的小鼠 T 细胞受体转导的外周血淋巴细胞 | 阶段
Phase 1, Phase 2
|
Date Added 2018-11-19 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03740256 |
Title二元溶瘤腺病毒与 HER2 特异性自体 CAR VST 联合治疗晚期 HER2 阳性实体瘤 | 阶段
第 1 阶段
|
Date Added 2018-11-14 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
CAdVEC |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03727763 |
Title西妥昔单抗和维莫非尼联合 FOLFIRI 治疗 BRAF V600E 突变的晚期结直肠癌 (IMPROVEMENT) | 阶段
第二阶段
|
Date Added 2018-11-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
cetuximab, Vemurafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03711058 |
TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2018-10-18 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Copanlisib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03692429 |
TitlealloSHRINK - 使用基于 NKG2D 的 CYAD-101 嵌合抗原受体 T 细胞的异体 NKG2D 标准 cHemotherapy 方案和免疫疗法 | 阶段
第 1 阶段
|
Date Added 2018-10-02 |
地点
Florida, United States
比利时 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
CYAD-101, FOLFIRI, FOLFOX |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03673787 |
Title伊帕塞替联合阿特珠单抗的试验 | 阶段
第 1 阶段
|
Date Added 2018-09-17 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Atezolizumab, Ipatasertib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
